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ORIGINAL ARTICLE
Peptic ulcer disease (PUD) is considered relatively
uncommon but is potentially life-threatening in
cases of childhood gastrointestinal disease.1 PUD
is a heterogeneous disease, which is determined
by various etiological factors. Helicobacter pylori in-
fection causes chronic gastritis and PUD in chil-
dren.2,3 In addition, it is a major cause of PUD in
adult patients, and the eradication of H. pylori from
adults with duodenal ulcer (DU) can prevent
ulcer recurrence.4,5 However, the rates of H. pylori-
related DU and gastric ulcer (GU) are lower 
in children than that in adults.6–8 Therefore, be-
sides assessing the real impact of H. pylori infec-
tion on PUD in children, other possible
etiological factors should be clarified, to assist in
choosing the appropriate treatment.
Chronic use of aspirin and non-steroidal anti-
inflammatory drugs (NSAIDs) predisposes adult
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Background/Purpose: Peptic ulcer disease (PUD) in children is relatively rare as compared with adults. This
study aimed to assess the etiology, clinical and histological characteristics, and treatment of PUD in children.
Methods: All children aged < 18 years with an endoscopic diagnosis of PUD were enrolled in a tertiary 
referral center. The demographic data, clinical, endoscopic, and histological findings were compared
between patients with different causes of PUD.
Results: From 1234 endoscopic examinations, 67 (5.4%) children (median age, 11.4 years) with gastric ulcer
(GU; n=27) or duodenal ulcer (DU; n=40) were included. Thirty-two (47.7%) of them had Helicobacter pylori
infection and 11 (16.5%) had previous use of non-steroidal anti-inflammatory drugs (NSAIDs). Non-H. pylori,
non-NSAID PUD was found in 24 (35.8%) patients. Children with H. pylori-related PUD had a significantly
higher mean age, antral chronic inflammatory score, rate of familial PUD, and presence of DU and nodular
gastritis than those with NSAID-related and non-H. pylori, non-NSAID PUD (p < 0.01). In contrast, chil-
dren with NSAID-related PUD had a higher rate of upper gastrointestinal bleeding, associated with acute
febrile disease, than those with H. pylori-related and non-H. pylori, non-NSAID PUD (p < 0.05). All but two
patients with non-H. pylori, non-NSAID PUD were disease free after H. pylori eradication and proton
pump inhibitor treatment for 1–2 months.
Conclusion: In children, H. pylori-related PUD is associated with familial peptic ulcer and the presence of
DU. However, short-term NSAID use is correlated highly with GU. The outcome of childhood PUD is good.
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cardiologic and rheumatologic patients to a high
prevalence of PUD development.9–11 The rela-
tionship between chronic use of these drugs and
childhood PUD is still controversial.12–14 Some
studies have reported that, in childhood, aspirin
and NSAID use is associated with a high preva-
lence of ulceration of the stomach and duodenum.
However, Keenan et al reported a low incidence
(0.7%) of gastropathy in 702 children with juve-
nile rheumatoid arthritis who were treated with
NSAIDs.14 In practice, NSAIDs are used widely in
healthy children and adults for acute febrile dis-
eases or pain control.15 Acute gastrointestinal
bleeding associated with the short-term use of
NSAIDs is a common adverse reaction, with a
high rate of hospitalization and mortality in devel-
oped countries.16–18 It is less clear about the 
adverse role of short-term NSAID use among chil-
dren and its correlation with PUD.
In contrast, there has been an increase in non-
H. pylori, non-NSAID PUD in adult and child-
hood patients in developed countries.19–21 This
could have resulted from improved sanitation and
a drop in H. pylori seroprevalence in such coun-
tries.22 In Taiwan, the prevalence of H. pylori infec-
tion in children has not decreased in the past
decade.23 Therefore, it was of interest to assess
whether the prevalence of H. pylori infection in
children with PUD was still high. We attempted 
to determine whether different characteristics of
PUD exist in children, and to highlight the role of
H. pylori infection and NSAID use in childhood
PUD in Taiwan.
Patients and Methods
Enrolled patients
From February 1999 to April 2008, children aged
<18 years who underwent upper gastrointestinal
endoscopy for various symptoms were analyzed
retrospectively. The medical records of children
who were diagnosed with DU or GU by en-
doscopy were analyzed. Patients who had a pre-
disposing factor such as acute stress caused by 
a severe underlying disease, iatrogenic trauma,
and previous treatment of H. pylori infection
were excluded.
Endoscopic examination and diagnosis 
of H. pylori infection
During endoscopic examination, gastric speci-
mens were obtained from the antrum and corpus.
The two antral biopsies were sent for H. pylori cul-
ture and rapid urea test. The other two specimens
from the antrum and corpus were embedded in
formalin for histological examination. H. pylori
infection was defined by positive culture or posi-
tive results for the rapid urea test and histology.
Histology of gastric biopsies
The same pathologist, unaware of the endoscopic
and culture results, analyzed the gastric histol-
ogy. The H. pylori density for each specimen used
a previously published scale: 0, no bacteria; 
1, one or two small clusters with < 10 bacteria; 
2, less than half the superficial crypt area
with < 10 bacteria in each crypt; 3, less than half
the area but with > 10 bacteria, or more than half
the area with < 10 bacteria in each crypt; 4, > 10
bacteria in foveola with some free areas; and
5, > 10 bacteria without a free area.8 The acute in-
flammatory score (range, 0–3), chronic inflamma-
tion score (range, 0–3), atrophic change (range,
0–3), and intestinal metaplasia (range, 0–3)
were graded using the updated Sydney system.24
Antimicrobial susceptibility test
Minimum inhibitory concentrations of amoxi-
cillin, clarithromycin and metronidazole were
determined by the Etest® (AB Biodisk, Solna,
Sweden). The Etest® was performed on Mueller–
Hinton sheep blood agar plates. Plates were incu-
bated for 72 hours at 35°C under microaerophilic
conditions. A strain was considered resistant if the
MIC was > 2 μg/mL of amoxicillin, > 1 μg/mL of
clarithromycin, and < 8 μg/mL of metronidazole,
respectively.25
Treatment and follow-up
Once the H. pylori-related peptic ulcers were diag-
nosed, proton pump inhibitor (PPI)-based triple
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therapy was prescribed for each patient according
to the susceptibility test for H. pylori, and 
clarithromycin-based triple therapy was used in
culture-negative H. pylori-infected patients. Suc-
cessful eradication was defined by follow-up 
endoscopy, or when 13C-urea breath test was neg-
ative for H. pylori 6 weeks after the completion of
drug therapy. Patients with H. pylori-negative PUD
were treated with lansoprazole (1 mg/kg/day,
maximum dose, 30mg/day) for 1–2 months. Heal-
ing of peptic ulcers was assessed by follow-up en-
doscopy performed 6 weeks after therapy, or 
by the resolution of dyspepsia, with a normal
hematocrit and negative result for fecal occult
blood after 2 and 6 months of follow-up.
Statistical analysis
The differences between patients with DU and
GU were assessed by the χ2 or independent t test
for nominal or continuous variables, respec-
tively. One-way analysis of variance with least
significant difference correction was used to ana-
lyze parametric differences between patient
groups. The Mann–Whitney and Kruskal–Wallis
tests were used to analyze the statistical signifi-
cance of non-parametric data of inflammatory
scores between groups. A value of p < 0.05 was
considered as significant.
Results
Prevalence and characteristics of PUD in
children
During a 10-year period, PUD was diagnosed by en-
doscopy in 67 (5.4%) out of 1234 children with
upper gastrointestinal symptoms. The median age
was 11.4 years (range, 1.5–18.0 years) and the male
to female ratio was 2.5 (48 boys and 19 girls).
Endoscopy revealed 40 cases (59.7%) of DUs and
27 cases (40.3%) of GUs. Eleven (16.5%) children
had a history of taking ulcerogenic drugs (1 involv-
ing aspirin, and 10 involving NSAIDs) 1 week be-
fore the onset of gastrointestinal symptoms.
Thirty-two (47.7%) of the 67 peptic ulcers were di-
agnosed as primary H. pylori infection. The others
(35.8%) were non-H. pylori, non-NSAID PUD. 
A positive family history of PUD was found in 
11 (16.4%) children. The most common presenta-
tion of the patients was acute or chronic abdominal
pain (80.6%), followed by upper gastrointestinal
bleeding (64.2%), anemia defined as hemoglobin
level <11g/dL (43.3%), and vomiting (41.8%).
Endoscopic features of children with DUs
and GUs
Among 40 children with DUs, 29 had H. pylori
infection. A characteristic endoscopic feature of
antral nodularity was found more frequently in H.
pylori-infected DU patients than in non-infected
ones (87.5% vs. 2.6%, p < 0.001). In addition,
three children with GU and H. pylori infection had
coexisting antral nodularity. Among 11 children
with GU and prior ulcerogenic drug use, nine
(81.8%) of them presented with single (n = 3) or
multiple (n = 6) circumferentially ulcerative mu-
cosal lesions over the pre-pyloric region (Figures A
and B). In contrast, in three children with GU and
H. pylori infection, one had a single ulceration of
the antrum, and the other two had single ulcera-
tion of the corpus.
Different characteristics between H. pylori,
NSAID, and non-H. pylori non-NSAID PUD
The Table shows the demographic, clinical and en-
doscopic features, and histology of children with
H. pylori-, NSAID-, or non-H. pylori, non-NSAID-
related PUD. Children with H. pylori-related PUD
had a significantly higher mean age (p<0.001) and
antral chronic inflammation score (p<0.001),
higher rate of familial PUD (p=0.007), and greater
presence of endoscopic DU (p<0.001) and nodu-
lar appearance (p<0.001) than those with NSAID-
related and non-H. pylori, non-NSAID PUD. In
contrast, children with NSAID-related PUD had a
higher rate of upper gastrointestinal bleeding
(p=0.02), associated with acute febrile disease
(p<0.001) and GU (p<0.001), than those with 
H. pylori-related and non-H. pylori, non-NSAID
PUD. None of the patients had mucosal atrophy in
the corpus and intestinal metaplasia in the antrum
and corpus.
Peptic ulcer disease in children
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Antimicrobial susceptibility testing and
eradication rate of H. pylori
Among 32 children with peptic ulcers and H. 
pylori infection, 21 (65.6%) of them had a posi-
tive culture for H. pylori. The antimicrobial sus-
ceptibility rates of H. pylori isolates were 100%,
76.2% and 85.7% for amoxicillin, clarithromycin
and metronidazole, by the Etest®, respectively.
There was only one strain (4.8%) that showed re-
sistance to clarithromycin and metronidazole.
Thirty patients had received eradication therapy
and complete follow-up. The per-protocol eradi-
cation rate of H. pylori in children with peptic
ulcer was 86.7%.
Follow-up and outcomes of childhood PUD
During a median of 2.8 years (range, 0.4–9.5
years) of follow-up, all patients showed disease
resolution. For H. pylori-related PUD, three pa-
tients with DU and one with GU failed initial erad-
ication therapy but were disease free after the
second course of anti-H. pylori treatment. All 
patients with ulcerogenic drug-related GU were
disease free. Two of 13 non-H. pylori, non-NSAID-
related PUD patients had unhealed ulceration
after 8 weeks of PPI treatment, but the ulceration
resolved with a subsequent course of PPI.
Discussion
Over the past decade, there have been only a 
few reports in the literature concerning PUD in
children. In our study, PUD was diagnosed in
5.4% of children who underwent upper gastroin-
testinal endoscopy for various symptoms. The low
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Figure. Children with gastric ulcer and previous ulcerogenic drug use usually presented with (A) large single or (B) mul-
tiple circumferentially ulcerative mucosal lesions over the pre-pyloric region. (C) In contrast, children with Helicobacter
pylori-related duodenal ulcer usually had a characteristic feature of nodular gastritis.
prevalence of PUD was consistent with other re-
ports, which suggests that, even in the era of en-
doscopy, PUD remains a rare cause of upper
gastrointestinal complaint in children.6,7 However,
in our study, a high proportion (64.2%) of chil-
dren presented with serious upper gastrointestinal
hemorrhage. This highlights that childhood PUD
is a potential life-threatening disorder, although
it rarely occurs.
H. pylori infection is a well-recognized cause of
chronic gastritis and plays an important role in the
pathogenesis of PUD in adults and children.2–7 As
in the present study, the prevalence of H. pylori-
related PUD in children has been shown to be
lower than in adults.2,6,7,26–28 The rate of H. pylori
infection among childhood PUD has been shown
to be 33–92% in patients with DU and 20–75% in
those with GU.2,3,6,7,29 However, there was still a
strong causal relationship between H. pylori and
childhood PUD, as compared with a low preva-
lence (12.3%) of H. pylori infection in children
aged 13–15 years in Taiwan.30 In contrast to the
chronic NSAID user, we demonstrated that 16.5%
of 67 children with PUD had a short course of ul-
cerogenic drug use for their febrile disease. Non-H.
pylori, non-NSAID-related childhood PUD was
found frequently (35.8%) in our patients, as by
other investigators.19–21 These results imply that
factors other than H. pylori infection and NSAID
use play an important role in childhood PUD.
The endoscopic findings differed between chil-
dren with PUD of different etiologies. Nodular
gastritis of the antrum was found in 90.7% of the
32 patients with H. pylori-related PUD (26 DUs
and 3 GUs). The characteristic antral nodularity
has been reported more frequently in children
than in adults with H. pylori infection.31–33 We
found a high prevalence (82%) of pre-pylorus cir-
cumferential ulceration in ulcerogenic drug users.
This suggests that it is a hallmark of acute adverse
effects of ulcerogenic drugs (especially NSAIDs) in
children.
In contrast to the close relationship between H.
pylori infection and PUD in adults, H. pylori-related
Peptic ulcer disease in children
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Table. Demographic data, clinical manifestations, endoscopic findings, and histology of children with Helicobacter pylori-
related, NSAID-related, and non-H. pylori, non-NSAID peptic ulcer disease (PUD)*
Non-H. pylori
H. pylori-related NSAID-related
non-NSAID PUD p
PUD (n = 32) PUD (n = 11)
(n = 24)
Demographic data
Mean age (yr) 13.5 4.5† 8.5†‡ < 0.001
Sex, male 22 (68.8) 9 (81.8) 17 (70.8) 0.710
Family history of peptic ulcers 10 (31.3) 0 (0)† 1 (4.2)† 0.007
Clinical manifestations
Abdominal pain 26 (81.3) 7 (63.6) 21 (87.5) 0.250
Duration of pain < 2 wk 10 (31.3) 4 (36.4) 9 (37.5) 0.780
Upper gastrointestinal bleeding 20 (62.5)‡ 11 (100) 12 (50.0)‡ 0.020
Anemia (hemoglobin < 10 g/dL) 15/28 (53.6) 4 (36.4) 10/21 (47.6) 0.620
Febrile disease within 1 wk 1 (3.1)‡ 8 (72.7) 4 (16.7) †‡ < 0.001
Endoscopy and histology
Duodenal ulcer 29 (90.6) 1 (9.1)† 10 (40.0)† < 0.001
Gastric ulcer 3 (9.4)‡ 10 (90.9) 14 (60.0)‡ < 0.001
Antral nodularity 28 (87.5) 0 (0)† 1 (4.2)† < 0.001
Antral CIS 2.7 1.4† 1.3† < 0.001
Antral AIS 1.5 0.8 0.2† 0.005
*Data presented as mean or n (%); †p < 0.05 vs. H. pylori-related PUD; ‡p < 0.05 vs. NSAID-related PUD. NSAID = non-steroidal anti-inflammatory drugs;
CIS = chronic inflammation score; AIS = acute inflammation score.
PUD, especially in GUs, was found less frequently
in children. Thus, we tried to find other character-
istic factors in DU-dominant, H. pylori-related
PUD and GU-dominant, NSAID-related PUD. As
shown in the Table, in addition to the presence of
DU (p<0.001), older age (p<0.001) and a family
history of peptic ulcers (p=0.007) were signifi-
cantly more frequent in the children with H. pylori-
related than NSAID-related PUD.2,3 Furthermore,
previous short-term use of ulcerogenic drugs was
related closely to the development of GU. These
findings might have been responsible for the
higher rate of H. pylori infection in DU than in 
GU patients, and imply that the mechanisms of 
ulcerogenesis in children taking NSAIDS are in-
deed different from those in adults with chronic
NSAID use.34
The purpose of taking NSAIDs in childhood
is usually the antipyretic effect rather than the
anti-inflammatory effect in adults.15 This is why
childhood GU is correlated highly with the oc-
currence of febrile disease. However, whether the
pathogens of febrile disease have a synergistic ef-
fect with NSAIDs to induce ulcer formation is
still unknown.
The incidence of non-H. pylori, non-NSAID
PUD in children has increased around the
world.20,21 However, as in this study, which had a
high proportion (50%) of patients with upper gas-
trointestinal bleeding, Chan et al suggested that
biopsy urea test is insufficient to diagnose H. pylori
infection in patients with bleeding.35 Xia et al
demonstrated that the presence of comorbid dis-
eases and the absence of epigastric pain/discom-
fort are independent factors for adult non-H. pylori,
non-NSAID DU.22 We also showed that the clini-
cal manifestations, and endoscopic and histologi-
cal findings are really different between childhood
non-H. pylori, non-NSAID PUD and H. pylori- and
NSAID-related PUD. The etiology and specific
characteristics of childhood non-H. pylori, non-
NSAID PUD requires further investigation.
H. pylori isolates from children have a high 
clarithromycin resistant rate, which leads to treat-
ment failure.25,36,37 In our country, the rates of re-
sistance to clarithromycin and metronidazole
have increased compared with a decade ago.25
This rapid evolution of antimicrobial resistance
of H. pylori in children has led us to be more con-
scientious in the treatment of childhood H. pylori
infection. In the present study, the overall eradi-
cation rate of H. pylori in children with PUD was
86.7%. This result was superior to that in
European studies (79.7%) of PUD patients.38
Moreover, we did not find that the eradication
rate was superior in children with clar-
ithromycin-based triple therapy according to the
antibiotic susceptibility test for H. pylori isolates
than in culture-negative patients with the same
regimen (p > 0.05). The cost–benefit of endo-
scopic antibiotic susceptibility testing for H. 
pylori eradication needs a larger-scale study.
In conclusion, we demonstrated that PUD is
an uncommon disorder in children. The etiol-
ogy, clinical characteristics, and histopathology
were different between H.pylori-, NSAID-, and
non-H.pylori, non-NSAID-related PUD in chil-
dren. In addition to H. pylori infection and ul-
cerogenic drugs, unknown factors are also
important in childhood PUD. Therefore, proper
and efficient diagnosis and treatment protocols
should be adopted for H. pylori eradication and
long-term ulcer healing.
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